Dentsply Sirona (NASDAQ: XRAY) reported Q3 EPS of $0.67, $0.35 better than the analyst estimate of $0.32. Revenue for the quarter came in at $895 million versus the consensus estimate of $839.02 million.

• Net sales of $895 million declined 7.0%. Organic sales declined 8.8%
• GAAP operating income of $82 million decreased 25.4%. Non-GAAP operating income of $197 million increased 14.3%
• GAAP EPS of $0.25 decreased 34.2%. Non-GAAP EPS of $0.67 increased 17.5%
• Cash flow from operations of $207 million

Don Casey, CEO commented: “Our third quarter results reflect a recovery in global dental markets, the actions we took to address pandemic related challenges, and the ongoing structural changes designed to improve our performance over the long-term. While we saw an encouraging improvement in business trends during the quarter, the outlook remains uncertain as a second wave of the pandemic impacts various countries around the world. We remain focused on delivering on our strategic imperatives to drive growth and innovation, while taking appropriate actions to manage our costs in the uncertain environment.”

Fiscal Year 2020 Outlook

As a result of the uncertainty around the duration of the COVID-19 pandemic and its impact on the business, the Company continues to not provide 2020 guidance.

For earnings history and earnings-related data on Dentsply Sirona (XRAY) click here.